» Articles » PMID: 38765062

Toll-like Receptor 7: A Novel Neuroimmune Target to Reduce Excessive Alcohol Consumption

Overview
Date 2024 May 20
PMID 38765062
Authors
Affiliations
Soon will be listed here.
Abstract

Toll-like receptors (TLRs) are a family of innate immune receptors that recognize molecular patterns in foreign pathogens and intrinsic danger/damage signals from cells. TLR7 is a nucleic acid sensing endosomal TLR that is activated by single-stranded RNAs from microbes or by small noncoding RNAs that act as endogenous ligands. TLR7 signals through the MyD88 adaptor protein and activates the transcription factor interferon regulatory factor 7 (IRF7). TLR7 is found throughout the brain and is highly expressed in microglia, the main immune cells of the brain that have also been implicated in alcohol drinking in mice. Upregulation of mRNA and protein has been identified in postmortem hippocampus and cortex from AUD subjects that correlated positively with lifetime consumption of alcohol. Similarly, and downstream signaling genes were upregulated in rat hippocampal and cortical slice cultures after chronic alcohol exposure and in these regions after chronic binge-like alcohol treatment in mice. In addition, repeated administration of the synthetic TLR7 agonists imiquimod (R837) or resiquimod (R848) increased voluntary alcohol drinking in different rodent models and produced sustained upregulation of IRF7 in the brain. These findings suggest that chronic TLR7 activation may drive excessive alcohol drinking. In the brain, this could occur through increased levels of endogenous TLR7 activators, like microRNAs and Y RNAs. This review explores chronic TLR7 activation as a pathway of dysregulated neuroimmune signaling in AUD and the endogenous small RNA ligands in the brain that could perpetuate innate immune responses and escalate alcohol drinking.

Citing Articles

Exploring genetic structures and shared sites between alcohol, cheese intake, and inflammatory bowel disease.

Huang Z, Yuan W Front Nutr. 2025; 12:1468457.

PMID: 39917747 PMC: 11798781. DOI: 10.3389/fnut.2025.1468457.


Regulating Immune Responses Induced by PEGylated Messenger RNA-Lipid Nanoparticle Vaccine.

Jo H, Jeoung J, Kim W, Jeoung D Vaccines (Basel). 2025; 13(1).

PMID: 39852793 PMC: 11768904. DOI: 10.3390/vaccines13010014.


A systematic review and meta-analysis on the transcriptomic signatures in alcohol use disorder.

Friske M, Torrico E, Haas M, Borruto A, Giannone F, Hade A Mol Psychiatry. 2024; 30(1):310-326.

PMID: 39242950 PMC: 11649567. DOI: 10.1038/s41380-024-02719-x.

References
1.
Guglas K, Kolodziejczak I, Kolenda T, Kopczynska M, Teresiak A, Sobocinska J . YRNAs and YRNA-Derived Fragments as New Players in Cancer Research and Their Potential Role in Diagnostics. Int J Mol Sci. 2020; 21(16). PMC: 7460810. DOI: 10.3390/ijms21165682. View

2.
Lein E, Hawrylycz M, Ao N, Ayres M, Bensinger A, Bernard A . Genome-wide atlas of gene expression in the adult mouse brain. Nature. 2006; 445(7124):168-76. DOI: 10.1038/nature05453. View

3.
. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1223-1249. PMC: 7566194. DOI: 10.1016/S0140-6736(20)30752-2. View

4.
Khalifa A, Ghoneim A . Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19. Curr Res Pharmacol Drug Discov. 2021; 2:100068. PMC: 8562070. DOI: 10.1016/j.crphar.2021.100068. View

5.
Vore A, Deak T . Alcohol, inflammation, and blood-brain barrier function in health and disease across development. Int Rev Neurobiol. 2021; 161:209-249. PMC: 9204474. DOI: 10.1016/bs.irn.2021.06.009. View